Catherine Wilson
Research Subjects
Research Interests
Catherine Wilson has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Boudreau
Department of Discovery Oncology, Genentech Inc, 1 DNA Way, 94080 South San Francisco, CA USA
1 shared publication - Anneleen Daemen
Department of Bioinformatics & Computational Biology, Genentech, Inc
1 shared publication Benjamin Haley
Molecular Biology, Genentech Inc., South San Francisco, CA, USA
1 shared publicationCharles Albert Tindell
Molecular Oncology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA
1 shared publicationDavid Arnott
Protein Chemistry, Genentech Inc., South San Francisco, CA, USA
1 shared publication- David Arnott
Genentech, Inc., 1 DNA Way, MS63, South San Francisco, CA, 94080, USA.
1 shared publication
Latest Publications
- 1 August 2017
- Published by Elsevier in Cancer Cell
- Vol. 32 (2) , 221-237.e13
Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure
- 1 August 2017
- Published by Elsevier in Cancer Cell
- Vol. 32 (2) , 221-237.e13
Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure
- Open Access
- 3 November 2014
- Published by Springer Nature in Cancer & Metabolism
- Vol. 2 (1) , 1-14
Metabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells
Accumulating preclinical and clinical evidence implicates epithelial-mesenchymal transition (EMT) in acquired resistance to anticancer drugs; however, mechanisms by which the mesenchymal state determines drug resistance remain unknown. To explore a potential role for altered cellular metabolism in EMT and associated drug resistance, we analyzed the metabolome and transcriptome of three lung cancer cell lines that were rendered drug resistant following experimental induction of EMT. This analysis revealed evidence of metabolic rewiring during EMT that diverts glucose to the TCA cycle. Such rewiring was at least partially mediated by the reduced expression of pyruvate dehydrogenase kinase 4 (PDK4), which serves as a gatekeeper of the TCA cycle by inactivating pyruvate dehydrogenase (PDH). Overexpression of PDK4 partially blocked TGFβ-induced EMT; conversely, PDK4 inhibition via RNAi-mediated knockdown was sufficient to drive EMT and promoted erlotinib resistance in EGFR mutant lung cancer cells. We identified a novel interaction between PDK4 and apoptosis-inducing factor (AIF), an inner mitochondrial protein that appears to play a role in mediating this resistance. In addition, analysis of human tumor samples revealed PDK4-low as a predictor of poor prognosis in lung cancer and that PDK4 expression is dramatically downregulated in most tumor types. Together, these findings implicate PDK4 as a critical metabolic regulator of EMT and associated drug resistance.
- 3 November 2014
- Published by Springer Nature in Cancer & Metabolism
- Vol. 2 (1) , 1-14
Open AccessMetabolic and transcriptional profiling reveals pyruvate dehydrogenase kinase 4 as a mediator of epithelial-mesenchymal transition and drug resistance in tumor cells
Accumulating preclinical and clinical evidence implicates epithelial-mesenchymal transition (EMT) in acquired resistance to anticancer drugs; however, mechanisms by which the mesenchymal state determines drug resistance remain unknown. To explore a potential role for altered cellular metabolism in EMT and associated drug resistance, we analyzed the metabolome and transcriptome of three lung cancer cell lines that were rendered drug resistant following experimental induction of EMT. This analysis revealed evidence of metabolic rewiring during EMT that diverts glucose to the TCA cycle. Such rewiring was at least partially mediated by the reduced expression of pyruvate dehydrogenase kinase 4 (PDK4), which serves as a gatekeeper of the TCA cycle by inactivating pyruvate dehydrogenase (PDH). Overexpression of PDK4 partially blocked TGFβ-induced EMT; conversely, PDK4 inhibition via RNAi-mediated knockdown was sufficient to drive EMT and promoted erlotinib resistance in EGFR mutant lung cancer cells. We identified a novel interaction between PDK4 and apoptosis-inducing factor (AIF), an inner mitochondrial protein that appears to play a role in mediating this resistance. In addition, analysis of human tumor samples revealed PDK4-low as a predictor of poor prognosis in lung cancer and that PDK4 expression is dramatically downregulated in most tumor types. Together, these findings implicate PDK4 as a critical metabolic regulator of EMT and associated drug resistance.